A phase II trial of cytarabine , cisplatin , and etoposide was conducted in 38 patients with refractory stage III and IV non-Hodgkin 's lymphoma .
Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.  A phase II trial of cytarabine , cisplatin , and etoposide was conducted in 38 patients with refractory stage III and IV non-Hodgkin 's lymphoma . There were two complete and nine partial responses (32%) among 35 evaluable patients. Response rate in patients with large cell lymphoma was 45%. The dose-limiting toxic effect was myelosuppression in 66% of patients.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.  A phase II trial of cytarabine , cisplatin , and etoposide was conducted in 38 patients with refractory stage III and IV non-Hodgkin 's lymphoma . There were two complete and nine partial responses (32%) among 35 evaluable patients. Response rate in patients with large cell lymphoma was 45%. The dose-limiting toxic effect was myelosuppression in 66% of patients.

            ### Response:
            cytarabine, cisplatin, etoposide
            